FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:91-93 January 3, 2008 Number 1 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Jaccard, A. PubMed Citation

To the Editor: Jaccard et al. (Sept. 13 issue)¹ report on a difficult trial comparing high-dose melphalan with melphalan plus dexamethasone in patients with immunoglobulin-light-chain (AL) amyloidosis, but their results must be interpreted with caution. The treatment-related mortality rate (24%) in the group that received high-dose melphalan is more than twice the rate in centers performing transplantations for AL amyloidosis.² The study by Jaccard et al. enrolled many patients with involvement of three or more organs (36%) and poor cardiac status, thereby introducing a bias in favor of melphalan plus dexamethasone.² Moreover, 10 of 37 patients in the group treated . . . [Full Text of this Article]

This article has been cited by other articles:

• Dember, L. M. (2009). Modern Treatment of Amyloidosis: Unresolved Questions. J. Am. Soc. Nephrol. 20: 469-472 [Abstract] [Full Text]  
• Wechalekar, A. D., Lachmann, H. J., Goodman, H. J. B., Bradwell, A., Hawkins, P. N., Gillmore, J. D. (2008). AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome. Blood 112: 4009-4016 [Abstract] [Full Text]